A Phase 1, First-in-Human, Open-Label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 424 in Subjects With Multiple Myeloma

Trial Profile

A Phase 1, First-in-Human, Open-Label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 424 in Subjects With Multiple Myeloma

Not yet recruiting
Phase of Trial: Phase I

Latest Information Update: 11 Jun 2018

At a glance

  • Drugs AMG-424 (Primary)
  • Indications Multiple myeloma
  • Focus Adverse reactions; First in man
  • Sponsors Amgen
  • Most Recent Events

    • 05 Jun 2018 Planned End Date changed from 6 Sep 2020 to 25 Oct 2020.
    • 05 Jun 2018 Planned primary completion date changed from 6 Sep 2020 to 25 Oct 2020.
    • 05 Jun 2018 Planned initiation date changed from 11 May 2018 to 29 Jun 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top